Jubilant Biosys Ltd. and Endo Pharmaceuticals have achieved a late-stage discovery milestone in their joint oncology program. This marks the third milestone in the two-year-old, multi-target partnership, and enables the collaboration to rapidly pursue a development candidate. As a part of the partnership, Jubilant delivers preclinical development candidates and has an option to participate in clinical development. Endo owns the development and commercial rights to the successful outcomes. Jubila...